COGT Stock Up 76% after 13-Day Win Streak

COGT: Cogent Biosciences logo
COGT
Cogent Biosciences

Cogent Biosciences (COGT) stock hit day 13 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 76% return. The company has gained about $1.0 Bil in value over the last 13 days, with its current market capitalization at about $1.3 Bil. The stock remains 60.1% above its value at the end of 2024. This compares with year-to-date returns of 7.1% for the S&P 500.

Comparing COGT Stock Returns With The S&P 500

The following table summarizes the return for COGT stock vs. the S&P 500 index over different periods, including the current streak:

Return Period COGT S&P 500
1D 2.4% -0.0%
13D (Current Streak) 75.9% 2.0%
1M (21D) 66.8% 4.4%
3M (63D) 156.5% 16.7%
YTD 2025 60.1% 7.1%
2024 32.7% 23.3%
2023 -49.1% 24.2%
2022 34.7% -19.4%

Gains and Losses Streaks: S&P 500 Constituents

There are currently 119 S&P constituents with 3 days or more of consecutive gains and 13 constituents with 3 days or more of consecutive losses.

Consecutive Days # of Gainers # of Losers
3D 109 1
4D 1 5
5D 7 1
6D 0 4
7D or more 2 2
Total >=3 D 119 13

 

Relevant Articles
  1. As Oil Prices Rise, What Happens to Devon Energy Stock?
  2. The Bear Case: How BKR Behaves During Market Shocks
  3. The Bear Case: How VST Behaves During Market Shocks
  4. The Bear Case: How KKR Behaves During Market Shocks
  5. The Bear Case: How HOOD Behaves During Market Shocks
  6. How Low Can SNPS Really Go In A Market Crash?

Key Financials for Cogent Biosciences (COGT)

Last 2 Fiscal Years:

Metric FY2023 FY2024
Revenues $- $-
Operating Income $-208.1 Mil $-275.9 Mil
Net Income $-192.4 Mil $-255.9 Mil

Last 2 Fiscal Quarters:

Metric 2024 FQ4 2025 FQ1
Revenues $- $-
Operating Income $-73.7 Mil $-74.9 Mil
Net Income $-67.9 Mil $-72.0 Mil

While COGT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.